Oteseconazole (VT-1161)
Phase 3Small molecule
Oteseconazole (VT-1161) is one of 40 small molecule programs targeting Vulvovaginal Candidiasis. It is currently in Phase 3.
2
Indications
4
Total Trials
1
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
48 competitors in Candidiasis
#DrugCompanyPhaseTrials
1Diflucan
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Mycamine
BBaxter Healthcare Corporation
Approved
Cancidas
FFresenius Kabi Oncology Ltd.
Approved
Eraxis
VVicuron Pharmaceuticals
Approved
Sporanox
SSebela Pharmaceuticals Development LLC
Approved
Vfend
PPrism Pharmaceuticals
Approved
Lotrimin
BayerPhase 3
Ambisome
GileadApproved
Mycostatin
GGood Molecules, LLC
Phase 3
Nizoral
WWim Janssens
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Candidiasis2 trials
Vulvovaginal Candidiasis1 trial
Oteseconazole in the Treatment of Adults With Vulvovaginal Candidiasis（VVC）
Not yet recruiting·—··NCT07044947·3,000 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Oteseconazole (VT-1161). EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- MMycovia Pharmaceuticals Inc.